RxDoctor Payments Data

Tamara Canterbury, APRN

Psychiatric/Mental Health · Ottawa, KSNPI 1255483772

Payments from drug & device makers

$513in general payments, 2019–2025

Across 21 payments — averaging $24.42 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Alkermes, Inc.$147
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$96
  • Teva Pharmaceuticals USA, Inc.$88
  • E.r. Squibb & Sons, L.L.C.$64
  • Supernus Pharmaceuticals, Inc.$35
  • Takeda Pharmaceuticals U.S.A., Inc.$26
  • plus $57 from 3 others

What the payments were for

  • Food & beverage$27654%
  • Education$23746%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$513 in reported general payments places this provider in the 45th percentile of 404 psychiatric/mental health providers in Kansas.

See all psychiatric/mental health providers in Kansas

Medicare billing

Part B allowed, 2024
$11,766
Medicare patients
46
Services billed
173

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
VraylarCariprazine Hcl48$82,687
AustedoDeutetrabenazine14$78,174
LybalviOlanzapine/Samidorphan Malate42$65,432
FanaptIloperidone17$52,643
Abilify MaintenaAripiprazole13$41,681
CaplytaLumateperone Tosylate24$36,762
RexultiBrexpiprazole23$31,371
Invega SustennaPaliperidone Palmitate14$27,265
QelbreeViloxazine Hcl13$13,540
TrintellixVortioxetine Hydrobromide26$11,167
Aripiprazole133$9,640
Divalproex Sodium ErDivalproex Sodium129$9,013
BelsomraSuvorexant19$8,825
Lurasidone Hcl35$8,124
Lisdexamfetamine Dimesylate43$6,977

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieVraylar, Viibryd$18$86,78660 claims
Teva Pharmaceuticals USA, Inc.Austedo, Loxapine$88$80,21436 claims
Otsuka America Pharmaceutical, Inc.Abilify Maintena, Rexulti$25$73,05236 claims
Alkermes, Inc.Lybalvi$147$65,43242 claims
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta$96$36,76224 claims
Supernus Pharmaceuticals, Inc.Qelbree$35$13,54013 claims
Takeda Pharmaceuticals U.S.A., Inc.Trintellix$26$11,16726 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 404 psychiatric/mental health providers in Kansas.

Other psychiatric/mental health in Ottawa

See the full list for Kansas

Where these figures come from

Is this you, or does something look wrong? →